{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:36:40Z","timestamp":1790145400125,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["106680\/Z\/14\/Z"],"award-info":[{"award-number":["106680\/Z\/14\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12936-018-2190-z","type":"journal-article","created":{"date-parts":[[2018,1,22]],"date-time":"2018-01-22T12:26:58Z","timestamp":1516624018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms"],"prefix":"10.1186","volume":"17","author":[{"given":"J. Kevin","family":"Baird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Battle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind E.","family":"Howes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,22]]},"reference":[{"key":"2190_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/B978-0-12-397900-1.00004-9","volume":"80","author":"JK Baird","year":"2012","unstructured":"Baird JK, Maguire JD, Price RN. Diagnosis and treatment of Plasmodium vivax malaria. Adv Parasitol. 2012;80:203\u201370.","journal-title":"Adv Parasitol"},{"key":"2190_CR2","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1126\/science.124.3220.484-a","volume":"124","author":"PE Carson","year":"1956","unstructured":"Carson PE, Flanagan CL, Ickes CE, Alving AS. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science. 1956;124:484\u20135.","journal-title":"Science"},{"key":"2190_CR3","doi-asserted-by":"publisher","first-page":"e1001339","DOI":"10.1371\/journal.pmed.1001339","volume":"9","author":"RE Howes","year":"2012","unstructured":"Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9:e1001339.","journal-title":"PLoS Med"},{"key":"2190_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/B978-0-12-407826-0.00004-7","volume":"81","author":"RE Howes","year":"2013","unstructured":"Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. G6PD deficiency: global distribution, genetic variants and primaquine therapy. Adv Parasitol. 2013;81:133\u2013201.","journal-title":"Adv Parasitol"},{"key":"2190_CR5","unstructured":"Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2016 (GBD 2016) population estimates 1980\u20132016. In: Battle K, editor. Seattle, WA: IHME, University of Washington; 2017."},{"key":"2190_CR6","unstructured":"United Nations Population Division\u2014Department of Economic and Social Affairs. World population prospects, The 2017 Revision. vol. DVD Edition. 2017."},{"key":"2190_CR7","unstructured":"United Nations Statistics Division. Abortion rate. 2017. http:\/\/data.un.org\/Data.aspx?d=GenderStat&f=inID%3A12 . Accessed 16 Aug 2017."},{"key":"2190_CR8","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/S2214-109X(15)00275-2","volume":"4","author":"H Blencowe","year":"2016","unstructured":"Blencowe H, Cousens S, Jassir FB, Say L, Chou D, Mathers C, et al. National, regional, and worldwide estimates of stillbirth rates in 2015, with trends from 2000: a systematic analysis. Lancet Glob Health. 2016;4:e98\u2013108.","journal-title":"Lancet Glob Health"},{"key":"2190_CR9","unstructured":"UNICEF. Infant and young child feeding. 2017. https:\/\/data.unicef.org\/topic\/nutrition\/infant-and-young-child-feeding\/ . Accessed 16 Aug 2017."},{"key":"2190_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4269\/ajtmh.16-0141","volume":"95","author":"RE Howes","year":"2016","unstructured":"Howes RE, Battle KE, Mendis KN, Smith DL, Cibulskis RE, Baird JK, et al. Global epidemiology of Plasmodium vivax. Am J Trop Med Hyg. 2016;95:15\u201334.","journal-title":"Am J Trop Med Hyg"},{"key":"2190_CR11","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1056\/NEJMc1301936","volume":"369","author":"JW Bennett","year":"2013","unstructured":"Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med. 2013;369:1381\u20132.","journal-title":"N Engl J Med"},{"key":"2190_CR12","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1128\/AAC.01879-12","volume":"57","author":"I Sutanto","year":"2013","unstructured":"Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, et al. Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother. 2013;57:1128\u201335.","journal-title":"Antimicrob Agents Chemother"},{"key":"2190_CR13","first-page":"196","volume-title":"World malaria report 2017","author":"WHO","year":"2017","unstructured":"WHO. World malaria report 2017. Geneva: World Health Organization; 2017. p. 196."},{"key":"2190_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.910","author":"A Gaedigk","year":"2017","unstructured":"Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M, Klein TE, et al. The Pharmacogene Variation (PharmVar) Consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin Pharmacol Ther. 2017. https:\/\/doi.org\/10.1002\/cpt.910 (Epub ahead of print).","journal-title":"Clin Pharmacol Ther."},{"key":"2190_CR15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/FPC.0b013e32831ebb30","volume":"19","author":"J Sistonen","year":"2009","unstructured":"Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogen Genom. 2009;19:170\u20139.","journal-title":"Pharmacogen Genom"},{"key":"2190_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","volume":"83","author":"A Gaedigk","year":"2008","unstructured":"Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83:234\u201342.","journal-title":"Clin Pharmacol Ther"},{"key":"2190_CR17","doi-asserted-by":"crossref","first-page":"e23061","DOI":"10.7554\/eLife.23061","volume":"6","author":"J Watson","year":"2017","unstructured":"Watson J, Taylor WR, Menard D, Kheng S, White NJ. Modelling primaquine-induced haemolysis in G6PD deficiency. Elife. 2017;6:e23061.","journal-title":"Elife"},{"key":"2190_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12936-017-1784-1","volume":"16","author":"K Thriemer","year":"2017","unstructured":"Thriemer K, Ley B, Bobogare A, Dysoley L, Alam MS, Pasaribu AP, et al. Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group. Malar J. 2017;16:141.","journal-title":"Malar J"},{"key":"2190_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1475-2875-12-112","volume":"12","author":"L Seidlein von","year":"2013","unstructured":"von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, et al. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malar J. 2013;12:112.","journal-title":"Malar J"},{"key":"2190_CR20","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12936-015-0958-y","volume":"14","author":"Vivax Working Group","year":"2015","unstructured":"Vivax Working Group. Targeting vivax malaria in the Asia Pacific: The Asia Pacific Malaria Elimination Network Vivax Working Group. Malar J. 2015;14:484.","journal-title":"Malar J"},{"key":"2190_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00210-003-0832-2","volume":"369","author":"UM Zanger","year":"2004","unstructured":"Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 2004;369:23\u201337.","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"2190_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1067\/mcp.2002.125783","volume":"72","author":"A Gaedigk","year":"2002","unstructured":"Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther. 2002;72:76\u201389.","journal-title":"Clin Pharmacol Ther"},{"key":"2190_CR23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01.fpc.0000239974.69464.f2","volume":"17","author":"J Sistonen","year":"2007","unstructured":"Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogen Genom. 2007;17:93\u2013101.","journal-title":"Pharmacogen Genom"},{"key":"2190_CR24","doi-asserted-by":"publisher","first-page":"e15085","DOI":"10.7554\/eLife.15085","volume":"6","author":"GM Clarke","year":"2017","unstructured":"Clarke GM, Rockett K, Kivinen K, Hubbart C, Jeffreys AE, Rowlands K, et al. Characterisation of the opposing effects of G6PD deficiency on cerebral malaria and severe malarial anaemia. Elife. 2017;6:e15085.","journal-title":"Elife"},{"key":"2190_CR25","doi-asserted-by":"publisher","first-page":"e0005606","DOI":"10.1371\/journal.pntd.0005606","volume":"11","author":"A Bardaji","year":"2017","unstructured":"Bardaji A, Martinez-Espinosa FE, Arevalo-Herrera M, Padilla N, Kochar S, Ome-Kaius M, et al. Burden and impact of Plasmodium vivax in pregnancy: a multi-centre prospective observational study. PLoS Negl Trop Dis. 2017;11:e0005606.","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-018-2190-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:12:30Z","timestamp":1660349550000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-018-2190-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,22]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2190"],"URL":"https:\/\/doi.org\/10.1186\/s12936-018-2190-z","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,22]]},"assertion":[{"value":"13 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"42"}}